Advances in medicine targeting fibroblast growth factor receptors in the treatment of advanced cholangiocarcinoma
10.3760/cma.j.cn113884-20220726-00304
- VernacularTitle:靶向成纤维细胞生长因子受体药物在晚期胆管癌中的研究进展
- Author:
Yanchun WANG
1
;
Zhihong ZHONG
;
Xi CHEN
;
Yan ZHANG
Author Information
1. 解放军联勤保障部队第九○○医院肿瘤内科，福州 350025
- Keywords:
Bile duct neoplasms;
Receptors, fibroblast growth factor;
Molecular targeted therapy
- From:
Chinese Journal of Hepatobiliary Surgery
2022;28(12):951-955
- CountryChina
- Language:Chinese
-
Abstract:
Cholangiocarcinoma is a malignant tumor of the biliary tract with high heterogeneity and poor prognosis. Surgery is the only cure for early cholangiocarcinoma, but about two thirds of the patients are already advanced at the time of initial diagnosis. First-line chemotherapy in patients with advanced cholangiocarcinoma does not lead to viable survival. In recent years, with the development of second-generation sequencing technology, potential targets in cholangiocarcinoma have been continuously discovered, and a series of clinical trials have been carried out accordingly. Among them, clinical trials of drugs targeting fibroblast growth factor receptors (FGFRs) have yielded promising results. This article reviews the current status and research progress of drugs targeting FGFRs in the treatment of advanced cholangiocarcinoma.
